{"id":11193,"date":"2021-05-11T16:19:02","date_gmt":"2021-05-11T15:19:02","guid":{"rendered":"https:\/\/ppr-antibioresistance.inserm.fr\/?p=11193"},"modified":"2023-06-06T14:46:03","modified_gmt":"2023-06-06T13:46:03","slug":"open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium","status":"publish","type":"post","link":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/","title":{"rendered":"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium"},"content":{"rendered":"\n

IMI AMR accelerator<\/a>\u2019s GNA NOW Consortium<\/a> is looking for a novel antibiotic program to progress to Investigational
New Drug (IND).<\/p>\n\n\n\n

Interested candidates are asked to submit a non-confidential Expression of Interest (EoI), which will be evaluated by the GNA NOW Review Committee. The top three submissions will be asked to provide a full proposal.<\/p>\n\n\n\n

Important deadlines<\/strong>
\u2022 Expression of Interest submission: Friday 18 June 2021
\u2022 Programme proposal submission: Wednesday 25 August 2021
For more details on what the Consortium is looking for, what\u2019s in it for interested candidates, and how to submit a proposal, please view the Open Call<\/a>.<\/p>\n\n\n\n

Make sure to also register for the GNA NOW Open Call webinar <\/a>on Wednesday 12 May, during which more details will be provided and time will be made for questions and answers.<\/p>\n\n\n\n

About GNA NOW<\/strong>
Established in July 2019, the GNA NOW Consortium is a European collaboration of 11 partners focused on progressing Gram-Negative antibiotics from lead optimization to the completion of Phase I trials. <\/p>\n\n\n\n

Working under the AMR Accelerator umbrella, the project is funded by the Innovative Medicines Initiative (IMI) with inkind contributions from industry partner, Evotec.<\/p>\n\n\n\n

Acknowledgement<\/strong>
This project has received funding from the Innovative Medicines Initiative 2 Joint Undertaking under grant agreement No 853979. This Joint Undertaking receives support from the European Union\u2019s Horizon 2020 research and innovation programme and EFPIA.<\/p>\n\n\n\n

Disclaimer<\/strong>
This communication reflects the views of the GNA NOW Consortium and neither IMI nor the European Union and EFPIA are liable for any use that may be made of the information contained herein.<\/p>\n\n\n\n

Project contacts<\/strong>
Dr. Kristina Orrling, Lygature: kristina.orrling@lygature.org<\/a>
Dr. Sophie Lagrange, Evotec: Sophie.lagrange@evotec.com<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

IMI AMR accelerator\u2019s GNA NOW Consortium is looking for a novel antibiotic program to progress to InvestigationalNew Drug (IND). Interested candidates are asked to submit a non-confidential Expression of Interest (EoI), which will be evaluated by the GNA NOW Review Committee. The top three submissions will be asked to provide a full proposal. Important deadlines\u2022 […]<\/p>\n","protected":false},"author":139,"featured_media":11201,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_links_to":"","_links_to_target":""},"categories":[31],"tags":[],"acf":[],"yoast_head":"\nOpen call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium - Interface nationale ANTIBIOR\u00c9SISTANCE<\/title>\n<meta name=\"description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium - Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"og:description\" content=\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\" \/>\n<meta property=\"og:site_name\" content=\"Interface nationale ANTIBIOR\u00c9SISTANCE\" \/>\n<meta property=\"article:published_time\" content=\"2021-05-11T15:19:02+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2023-06-06T13:46:03+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"735\" \/>\n\t<meta property=\"og:image:height\" content=\"355\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"\u00c9milie Noguez\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"\u00c9crit par\" \/>\n\t<meta name=\"twitter:data1\" content=\"\u00c9milie Noguez\" \/>\n\t<meta name=\"twitter:label2\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\"},\"author\":{\"name\":\"\u00c9milie Noguez\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\"},\"headline\":\"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium\",\"datePublished\":\"2021-05-11T15:19:02+00:00\",\"dateModified\":\"2023-06-06T13:46:03+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\"},\"wordCount\":286,\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg\",\"articleSection\":[\"Actualit\u00e9s\"],\"inLanguage\":\"fr-FR\"},{\"@type\":[\"WebPage\",\"ItemPage\"],\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\",\"name\":\"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium - Interface nationale ANTIBIOR\u00c9SISTANCE\",\"isPartOf\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg\",\"datePublished\":\"2021-05-11T15:19:02+00:00\",\"dateModified\":\"2023-06-06T13:46:03+00:00\",\"description\":\"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.\",\"breadcrumb\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg\",\"width\":735,\"height\":355,\"caption\":\"Cr\u00e9dit : Pixabay\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Accueil\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Infos pratiques & communications\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Actualit\u00e9s\",\"item\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"name\":\"Interface nationale ANTIBIOR\u00c9SISTANCE\",\"description\":\"PPR Antibior\u00e9sistance - Inserm\",\"publisher\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization\",\"name\":\"Inserm\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"contentUrl\":\"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg\",\"width\":1,\"height\":1,\"caption\":\"Inserm\"},\"image\":{\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/\"}},{\"@type\":\"Person\",\"@id\":\"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3\",\"name\":\"\u00c9milie Noguez\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium - Interface nationale ANTIBIOR\u00c9SISTANCE","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/","og_locale":"fr_FR","og_type":"article","og_title":"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium - Interface nationale ANTIBIOR\u00c9SISTANCE","og_description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","og_url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/","og_site_name":"Interface nationale ANTIBIOR\u00c9SISTANCE","article_published_time":"2021-05-11T15:19:02+00:00","article_modified_time":"2023-06-06T13:46:03+00:00","og_image":[{"width":735,"height":355,"url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg","type":"image\/jpeg"}],"author":"\u00c9milie Noguez","twitter_card":"summary_large_image","twitter_misc":{"\u00c9crit par":"\u00c9milie Noguez","Dur\u00e9e de lecture estim\u00e9e":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#article","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/"},"author":{"name":"\u00c9milie Noguez","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3"},"headline":"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium","datePublished":"2021-05-11T15:19:02+00:00","dateModified":"2023-06-06T13:46:03+00:00","mainEntityOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/"},"wordCount":286,"publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg","articleSection":["Actualit\u00e9s"],"inLanguage":"fr-FR"},{"@type":["WebPage","ItemPage"],"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/","name":"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium - Interface nationale ANTIBIOR\u00c9SISTANCE","isPartOf":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage"},"thumbnailUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg","datePublished":"2021-05-11T15:19:02+00:00","dateModified":"2023-06-06T13:46:03+00:00","description":"Informations, \u00e9v\u00e8nements et actualit\u00e9s autour de l'Antibior\u00e9sistance en France et \u00e0 l'international.","breadcrumb":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#primaryimage","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2021\/05\/Top3.jpg","width":735,"height":355,"caption":"Cr\u00e9dit : Pixabay"},{"@type":"BreadcrumbList","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/open-call-to-fund-an-eu-based-novel-antibiotic-compound-to-progress-to-a-clinical-candidate-by-the-gna-now-consortium\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Accueil","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/"},{"@type":"ListItem","position":2,"name":"Infos pratiques & communications","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/"},{"@type":"ListItem","position":3,"name":"Actualit\u00e9s","item":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/informations-et-communications\/actualites\/"},{"@type":"ListItem","position":4,"name":"Open call to fund an EU-based novel antibiotic compound to progress to a clinical candidate, by the GNA NOW Consortium"}]},{"@type":"WebSite","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#website","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","name":"Interface nationale ANTIBIOR\u00c9SISTANCE","description":"PPR Antibior\u00e9sistance - Inserm","publisher":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#organization","name":"Inserm","url":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","contentUrl":"https:\/\/ppr-antibioresistance.inserm.fr\/wp-content\/uploads\/2020\/05\/logo-inserm-ppra.svg","width":1,"height":1,"caption":"Inserm"},"image":{"@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/logo\/image\/"}},{"@type":"Person","@id":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/#\/schema\/person\/6ae79ca06cbeaec66ef5e976b54606b3","name":"\u00c9milie Noguez"}]}},"publishpress_future_action":{"enabled":false,"date":"2026-04-11 14:28:59","action":"change-status","newStatus":"private","terms":[],"taxonomy":"category"},"post_mailing_queue_ids":[],"_links":{"self":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/11193"}],"collection":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/users\/139"}],"replies":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/comments?post=11193"}],"version-history":[{"count":2,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/11193\/revisions"}],"predecessor-version":[{"id":17839,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/posts\/11193\/revisions\/17839"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media\/11201"}],"wp:attachment":[{"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/media?parent=11193"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/categories?post=11193"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/ppr-antibioresistance.inserm.fr\/fr\/wp-json\/wp\/v2\/tags?post=11193"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}